Sugammadex may be a safe general anesthetic for patients with JS.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Joubert syndrome (JS) is a rare genetic disorder that affects the cerebellum, controlling balance, and coordination, and it usually presents a molar tooth sign on magnetic resonance imaging.
📊
Key Findings & Data:It is characterized by ataxia, an abnormal breathing pattern referred to as hyperpnea, sleep apnea, hypotonia, and abnormal eye and tongue movements.
💡
Conclusion & Impact:Sugammadex may be a safe general anesthetic for patients with JS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Joubert syndrome (JS) is a rare genetic disorder that affects the cerebellum, controlling balance, and coordination, and it usually presents a molar tooth sign on magnetic resonance imaging. It is characterized by ataxia, an abnormal breathing pattern referred to as hyperpnea, sleep apnea, hypotonia, and abnormal eye and tongue movements. Because of sensitivity to respiratory depressant agents, including opiates, nitrous oxide, and neuromuscular blockers, and potential difficult airways, anesthetic management requires attention. Sugammadex binds to rocuronium and is a reverse neuromuscular blocker. In this study, two cases of JS where sugammadex was used for general anesthesia are presented. Sugammadex may be a safe general anesthetic for patients with JS.
🔖
Cite This Article
CANPOLAT, D. G., YILDIRIM, M. D., DOĞAN, S., DOĞRUEL, F., PER, H., CANPOLAT, M. (2017). Sugammadex and Genaral Anesthesia in Two Pediatric Patients with Joubert Syndrome: Case Report. Erciyes Medical Journal, Cilt: 39 - Sayı: 1, 35–36. https://ajindex.com/articles/223488
Joubert M, Eisenring JJ, Andermann F. Familial dysgenesis of the ver- mis: a syndrome of hyperventilation, abnormal eye movements and retardation. Neurology 1968; 18(3): 302-3.
Brancati F, Dallapiccola B, Valente EM. Joubert Syndrome and related disorders. Orphanet J Rare Dis 2010; 5: 20. [CrossRef] Vodopich DJ, Gordon GJ. Anesthetic management in Joubert syn- drome. Paediatr Anaesth. 2004; 14: 871-3 [CrossRef] Harbe W, Sims C, D'Souza M. Anesthetic management of children with Joubert syndrome.Paediatr Anaesth 1997; 7: 251-3. [CrossRef] Buntenbroich S, Dullenkopf A. Total intravenous anesthesia in a patient with Joubert-Boltshauser syndrome. Paediatr Anaesth 2013; 23(2): 204-5. [CrossRef] Lien CA. Development and potential clinical impairment of ultra-short- acting neuromuscular blocking agents. Br J Anaesth 2011; 107: i60-71. [CrossRef] Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, et al. A novel concept of reversing neuromuscular block: chemical en- capsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41(2): 266-70. [CrossRef] Curtis R, Lomax S, Patel B. Use of sugammadex in a 'can't intubate, can'tventilate' situation. Br J Anaesth 2012; 108(4): 612-4. [CrossRef] Kumandas S, Akcakus M, Coskun A, Gumus H. Joubert syndrome: review and report of seven new cases. Eur J Neurol 2004; 11(8): 505- 10. [CrossRef] Matthews NC. Anaesthesia in an infant with Joubert's syndrome. An- aesthesia 1989; 44: 920-1. [CrossRef] Platis CM, Kachko L, Trabikin E, Simhi E, Bahar M, Katz J. Postoper- ative respiratory complications in Joubert syndrome. Paediatr Anaesth 2006; 16(7): 799-800. [CrossRef] Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversa lmedication for preventing postoperative residual neuromuscu- lar blockade. Cochrane Database Syst Rev 2009; 7(4): CD007362.